ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Below Fifty Day Moving Average of $57.70

Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $57.70 and traded as low as $56.26. ProShares Ultra Nasdaq Biotechnology shares last traded at $58.09, with a volume of 230,404 shares traded.

ProShares Ultra Nasdaq Biotechnology Stock Performance

The firm’s 50 day moving average price is $57.70 and its 200-day moving average price is $52.14.

ProShares Ultra Nasdaq Biotechnology Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, March 27th. Investors of record on Thursday, March 21st were given a dividend of $0.0403 per share. The ex-dividend date was Wednesday, March 20th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Vontobel Holding Ltd. raised its holdings in ProShares Ultra Nasdaq Biotechnology by 11.6% in the 1st quarter. Vontobel Holding Ltd. now owns 3,321 shares of the exchange traded fund’s stock valued at $206,000 after acquiring an additional 344 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in ProShares Ultra Nasdaq Biotechnology by 25.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,495 shares of the exchange traded fund’s stock valued at $135,000 after acquiring an additional 504 shares during the last quarter. UBS Group AG raised its holdings in ProShares Ultra Nasdaq Biotechnology by 213.6% in the 3rd quarter. UBS Group AG now owns 1,151 shares of the exchange traded fund’s stock valued at $55,000 after acquiring an additional 784 shares during the last quarter. Toth Financial Advisory Corp raised its holdings in ProShares Ultra Nasdaq Biotechnology by 17.3% in the 4th quarter. Toth Financial Advisory Corp now owns 11,241 shares of the exchange traded fund’s stock valued at $641,000 after acquiring an additional 1,655 shares during the last quarter. Finally, Simplex Trading LLC raised its holdings in ProShares Ultra Nasdaq Biotechnology by 5,408.9% in the 4th quarter. Simplex Trading LLC now owns 2,479 shares of the exchange traded fund’s stock valued at $141,000 after acquiring an additional 2,434 shares during the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.